Wuhan Keqian Biology Co., Ltd., commonly referred to as Keqian Biology, is a leading player in the biotechnology industry, headquartered in Wuhan, China. Established in 2005, the company has made significant strides in the development and production of innovative biological products, primarily focusing on molecular diagnostics and biopharmaceuticals. With a strong presence in both domestic and international markets, Keqian Biology is renowned for its high-quality reagents and diagnostic kits that cater to various sectors, including healthcare and research. The company’s commitment to research and development has positioned it as a trusted name in the industry, with notable achievements in product innovation and quality assurance. Keqian Biology continues to advance the field of biotechnology, offering unique solutions that meet the evolving needs of its clients.
How does Wuhan Keqian Biology Co.,Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Wuhan Keqian Biology Co.,Ltd's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Wuhan Keqian Biology Co., Ltd, headquartered in China (CN), currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their total emissions, including Scope 1, Scope 2, and Scope 3 emissions, are not provided. Additionally, there are no documented reduction targets or climate pledges from the company, indicating a lack of formal commitments to reduce carbon emissions at this time. The absence of emissions data and reduction initiatives suggests that Wuhan Keqian Biology Co., Ltd may still be in the early stages of developing a comprehensive climate strategy. As the company operates within the biotechnology sector, it is essential for them to consider establishing measurable climate commitments and reduction targets to align with industry standards and contribute to global climate goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Wuhan Keqian Biology Co.,Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

